5.

5 in

Cynocort Triamcinolone Acetonide BP

Injection
Injectable Suspension

COMPOSITION:
Cynocort Injection: Each 1 mL vial Contains- Triamcinolone Acetonide BP 40 mg.

INDICATION:
Cynocort is indicated for-
Alleviating the joint pain, swelling and stiffness associated with rheumatoid arthritis and osteoarthrosis
with an inflammatory component, also for bursitis, epicondylitis and tenosynovitis.

DOSAGE & ADMINISTRATION:

The dose of Cynocort is dependent on the size of the joint to be treated and on the severity of the
condition. Doses of 2.5-5 mg (0.0625- 0.1250 mL) for smaller joint and 5-15mg (0.125-0.375 mL) for
larger joints usually alleviate the symptoms. Cynocort 40 mg/mL is available to facilitate administration
of larger doses.

CONTRAINDICATION:
Hypersensitivity to any of the ingredients. Systemic infections unless specific anti-infective therapy is
employed. Administration by intravenous or intrathecal injection.

WARNING AND PRECAUTION:

Particular care is required when considering use of systemic corticosteroids in patients with the
following conditions and frequent patient monitoring is necessary. Diverticulitis, thrombophlebitis,
existing or previous history of severe affective disorders (especially previous steroid psychosis),
exanthematous diseases, chronic nephritis, or renal insufficiency, metastatic carcinoma, osteoporosis
8.8 in

(post-menopausal females are particularly at risk); in patients with an active peptic ulcer (or a history
of peptic ulcer).

SIDE-EFFECT:
Muscle weakness, fatigue, steroid myopathy, loss of muscle mass, osteoporosis, dyspepsia,
pancreatitis, impaired wound healing, thin fragile skin, facial erythema, Euphoria, psychological
dependence, depression, insomnia, convulsions etc.

USE IN PREGNANCY & LACTATION:

Pregnancy Category-C.
As with all drugs, Triamcinolone should only be prescribed when the benefits to the mother and child
outweigh the risks.
Corticosteroids may pass into breast milk, although no data are available for Triamcinolone.

DRUG INTERACTION:
Barbiturates, phenytoin, rifampicin, rifabutin, carbamazepine, primidone and aminoglutethimide may
enhance the metabolic clearance of corticosteroids, resulting in decreased therapeutic effects.
Food Interaction:
No interactions found

STORAGE:
Store at controlled room temperature (200C-250C), avoid freezing & protect from light. Keep out of
reach of children.

COMMERCIAL PACK:
Cynocort Injection: Each box contains- 1 vial of 1 mL injection & sterile syringe.

Manufactured by:
Techno Drugs Unit-2 TECHNO DRUGS LTD.
B.K. Bari, Mirzapur, Gazipur. Revision No.: 01
 5.5 in

mvB‡bvKU©
Uªvqvgwm‡bv‡jvb A¨vwm‡UvbvBW wewc
Bb‡RKkb

Bb‡RK‡Uej mvm&‡cbkb
Dcv`vb
mvB‡bvKU© Bb‡RKkbt cÖwZ 1 wg.wj. fvqv‡j i‡q‡Q- Uªvqvgwm‡bv‡jvb A¨vwm‡UvbvBW wewc 40 wg. MÖv.|

wb‡`©kbv
wiDgvU‡qW Av_ª©vBwUmRwbZ Aw¯’mw܇Z e¨_v, dz‡j hvIqv, AbgbxqZv Ges Aw÷IAv‡_ª©vwmm mn evm©vBwUm, GwcKÛvBjvBwUm Ges
†U‡bvmvB‡bvfvBwUm G mvB‡bvKU© wb‡`©wkZ|

†mebgvGv I †mebwewa
mvB‡bvKU© Gi ‡meb gvGv Aw¯’mwÜi AvKviI Ae¯’vi ZxeªZvi Dci wbf©i K‡i| 2.5-5 wg.MÖv. (.0625-0.1250 wg.wj.) †QvU
Aw¯’mwÜi Rb¨ Ges 5-15 wg.MÖv. (.125-.375 wg.wj.) eo Aw¯’mwÜi Rb¨ wb‡`©wkZ|
‡ewk gvÎvq cÖ‡qv‡Mi Rb¨ mvB‡bvKU© 40 wg.MÖv./wg.wj. fvqv‡j i‡q‡Q|

weiƒcwb‡`©kbv
wm‡÷wgK msµgb †hLv‡b wbw`©ó Gw›U-B‡dw±f e¨envi Kiv nqwb| AšÍwkiv ev B›Uªv‡_Kvj c‡_ weiƒcwb‡`©wkZ|

cvk^© cÖwZwµqv
gvsm‡ckxi `~e©jZv, AembœZv, †÷i‡qWgv‡qvc¨vw_, gvsm‡ckx K‡g hvIqv, Aw÷I‡cv‡ivwmm, e`nRg, c¨vbwµqvUvBwUm I ÿZ
ïKv‡Z wej¤^|

c~e©mZK©Zv
8.8 in

KwU©‡Kv‡÷i‡qW e¨env‡ii ‡ÿ‡Î we‡kl mZK©Zv Aej¤^b Kiv DwPZ| WvBfvwU©‡KvjvBwUm, _ª‡¤^v‡d¬evBwUm, c~e© BwZnvm Av‡Q hv
eZ©gv‡b Dcw¯’Z, A¨vK‡Rb‡_‡gUvmwWwRR, µwbK †bd«vBwUm, †gUv‡÷wUK Kviwm‡bvgv Ges mwµq †ccwUK Avjmv‡ii †ivMx|

Ab¨ Ily‡ai mv‡_ wewµqv

eviwewUD‡iUm, wdbvBU‡qb, widvgwcwmb, widvweDwUb, Kvievgv‡RcvBb, wcÖwg‡WvbKwU©‡Kv‡÷i‡qW Gi wecvKxq wbtmib evovq
ZvB Gi Kvh©KvixZv K‡g hvq|

Mf©ve¯’vq I ¯Íb¨`vbKv‡j e¨envi

‡cÖM‡bwÝ K¨vUvMwi-wm|
Ab¨vb¨ Jl‡ai gZ hLb Uªvqvgwm‡bvjb A¨vwm‡UvbvBW e¨env‡i gv I wkï Df‡qiB ÿwZi Zzjbvq DcKvixZv †ekx ïaygvÎ †mB
†ÿ‡ÎB e¨envh©| KwU©‡Kv‡÷i‡qW gvZ…`y» Øviv wbtm„Z n‡Z cv‡i, Z‡e Uªvqvgwm‡bvjb Gi Dci Ggb †Kvb Z_¨ cvIqv hvqwb|

gvÎvwaK¨
jÿb †`‡L mnvqK wPwKrmv wb‡Z n‡e|

msiÿb
200-250 †mt ZvcgvÎvi g‡a¨ msiÿb Kiæb| wd«‡R ivLv †_‡K weiZ _vKzb Ges Av‡jv †_‡K `~‡i ivLyb| wkï‡`i bvMv‡ji evB‡i
ivLyb|

mieivn
mvB‡bvKU© Bb‡RKkbt cÖwZwU ev‡· i‡q‡Q- 1 wg.wj. Bb‡RKkb mg„× 1wU fvqvj Ges GKwU Rxevbygy³ wmwiÄ|

cÖ¯‘ZKviKt
†UK‡bv WªvMm BDwbU-2 †UK‡bv WªvMm wjt
we.‡K. evox, wgR©vcyi, MvRxcyi|